Connaught licenses tuberculosis and meningitis vaccines from ID Vaccine and North American Vaccine.
CONNAUGHT PAYS $4.5 MIL. TO LICENSE IDV TUBERCULOSIS VACCINE, Pasteur Merieux-Connaught and ID Vaccine Corp. announced Oct. 2. "IDV will receive an upfront licensing fee, development support payments and an equity investment totaling $4.5 mil." in exchange for exclusive worldwide rights to the firm's TB subunit vaccine technology, the companies said. IDV also will receive "substantial" milestone payments and royalties on product sales.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth